PART I FINANCIAL INFORMATION Item 1. Financial Statements This section presents the unaudited condensed consolidated financial statements of AirSculpt Technologies, Inc. for specific periods, including balance sheets, statements of operations, comprehensive income, equity changes, cash flows, and detailed notes Condensed Consolidated Balance Sheets This table provides a snapshot of the company's assets, liabilities, and stockholders' equity at specific dates | ($000s) | September 30, 2023 (Unaudited) | December 31, 2022 | | :--------------------------------- | :----------------------------- | :------------------ | | Assets | | | | Total current assets | $16,410 | $16,676 | | Property and equipment, net | $28,909 | $24,206 | | Intangible assets, net | $47,534 | $51,099 | | Goodwill | $81,734 | $81,734 | | Total assets | $204,123 | $200,759 | | Liabilities | | | | Total current liabilities | $19,793 | $22,318 | | Long-term debt, net | $70,603 | $81,420 | | Total liabilities | $119,932 | $129,993 | | Stockholders' Equity | | | | Total stockholders' equity | $84,191 | $70,766 | Condensed Consolidated Statements of Operations This table details the company's revenues, expenses, and net income or loss over specific reporting periods | (in $000s, except per share) | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--------------------------- | :------------------------------ | :------------------------------ | :----------------------------- | :----------------------------- | | Revenue | $46,793 | $38,892 | $148,309 | $128,090 | | Total operating expenses | $45,838 | $40,267 | $140,230 | $126,673 | | Income/(loss) from operations| $955 | $(1,375) | $8,079 | $1,417 | | Net (loss)/income | $(1,667) | $(7,377) | $95 | $(7,487) | | Basic EPS | $(0.03) | $(0.13) | $0.00 | $(0.13) | | Diluted EPS | $(0.03) | $(0.13) | $0.00 | $(0.13) | Condensed Consolidated Statements of Other Comprehensive Income/(Loss) This table presents the components of other comprehensive income or loss, which are not included in net income | ($000s) | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :---------------------------------- | :------------------------------ | :------------------------------ | :----------------------------- | :----------------------------- | | Net (loss)/income | $(1,667) | $(7,377) | $95 | $(7,487) | | Change in foreign currency translation adjustment | $(106) | $64 | $(141) | $64 | | Total other comprehensive (loss)/income | $(106) | $64 | $(141) | $64 | | Comprehensive loss | $(1,773) | $(7,313) | $(46) | $(7,423) | Condensed Consolidated Statements of Changes in Stockholders' Equity This section outlines the changes in the company's equity accounts over specific periods, including common stock, additional paid-in capital, and accumulated deficit | ($000s) | Balance at Dec 31, 2022 | Balance at Sep 30, 2023 | | :--------------------------------- | :---------------------- | :---------------------- | | Common Stock (Amount) | $56 | $57 | | Additional Paid-in Capital | $85,858 | $99,328 | | Accumulated Other Comprehensive Loss | $(76) | $(217) | | Accumulated Deficit | $(15,072) | $(14,977) | | Total Stockholders' Equity | $70,766 | $84,191 | - For the nine months ended September 30, 2023, equity-based compensation was $13,483 thousand, and net income was $95 thousand23 - Dividends paid were $206 thousand23 Condensed Consolidated Statements of Cash Flows This table summarizes the cash inflows and outflows from operating, investing, and financing activities | ($000s) | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--------------------------------- | :----------------------------- | :----------------------------- | | Net cash provided by operating activities | $19,090 | $17,807 | | Net cash used in investing activities | $(8,092) | $(10,726) | | Net cash used in financing activities | $(11,954) | $(24,828) | | Net decrease in cash and cash equivalents | $(956) | $(17,747) | | Cash and cash equivalents, End of period | $8,660 | $7,600 | Notes to Condensed Consolidated Financial Statements This section provides detailed explanations and disclosures supporting the condensed consolidated financial statements NOTE 1 – ORGANIZATION AND SUMMARY OF KEY ACCOUNTING POLICIES This note describes the company's formation, business model, and significant accounting policies - AirSculpt Technologies, Inc. was formed on June 30, 2021, and completed its IPO on October 28, 20212728 - The Company operates as a holding company, providing practice management services to professional associations (PAs) in the US, Canada, and the UK, focusing on specialty, minimally invasive liposuction33 - Revenue is recognized when specialty, minimally invasive liposuction services are performed, with payment typically received in advance36 - Deferred revenue and patient deposits reflect payments for services yet to be performed38 Amortization of Deferred Financing Costs | Period | 2023 (approx. $ millions) | 2022 (approx. $ millions) | | :--------------------------------- | :---------------- | :---------------- | | Three Months Ended September 30 | $0.3 | $0.2 | | Nine Months Ended September 30 | $0.8 | $0.7 | Advertising Expenses | Period | 2023 (approx. $ millions) | 2022 (approx. $ millions) | | :--------------------------------- | :---------------- | :---------------- | | Three Months Ended September 30 | $6.5 | $5.4 | | Nine Months Ended September 30 | $19.5 | $15.4 | Effective Tax Rate | Period | 2023 | 2022 | | :--------------------------------- | :--- | :--- | | Three Months Ended September 30 | (89.2)% | (134.6)% | | Nine Months Ended September 30 | 96.4% | (119.9)% | NOTE 2 – GOODWILL AND INTANGIBLES, NET This note details the company's goodwill and intangible assets, including their carrying values and amortization - Goodwill remained constant at $81.7 million as of September 30, 2023, and December 31, 2022, with no triggering events for impairment during the periods5455 Intangible Assets, Net ($000s) | Category | September 30, 2023 | December 31, 2022 | Useful Life | | :--------------------------------- | :----------------- | :---------------- | :---------- | | Technology and know-how | $53,600 | $53,600 | 15 years | | Trademarks and tradenames | $17,700 | $17,700 | 15 years | | Total Intangible Assets (Gross) | $71,300 | $71,300 | | | Accumulated amortization | $(23,766) | $(20,201) | | | Total intangible assets, net | $47,534 | $51,099 | | - Aggregate amortization expense on intangible assets was approximately $1.2 million for both the three months ended September 30, 2023 and 2022, and $3.6 million for both the nine months ended September 30, 2023 and 202256 NOTE 3 – PROPERTY AND EQUIPMENT, NET This note provides a breakdown of the company's property and equipment, including medical equipment, office equipment, and leasehold improvements Property and Equipment, Net ($000s) | Category | September 30, 2023 | December 31, 2022 | | :--------------------------------- | :----------------- | :---------------- | | Medical equipment | $10,809 | $8,906 | | Office and computer equipment | $833 | $551 | | Furniture and fixtures | $4,054 | $3,457 | | Leasehold improvements | $21,140 | $14,614 | | Construction in progress | $2,158 | $2,854 | | Less: Accumulated depreciation | $(10,085) | $(6,176) | | Property and equipment, net | $28,909 | $24,206 | - Depreciation expense increased to approximately $1.4 million for the three months ended September 30, 2023, from $0.8 million in the prior year, and to $3.9 million for the nine months ended September 30, 2023, from $2.3 million in the prior year57 NOTE 4 – DEBT This note details the company's debt obligations, including term loans, revolving credit facilities, and associated costs - On November 7, 2022, the Company entered into a new credit agreement for an $85.0 million term loan and a $5.0 million revolving loan facility, maturing November 7, 202758122 - Proceeds from the new credit agreement were used to pay off the previous $83.6 million credit facility58122 - On September 29, 2023, the Company voluntarily prepaid $10.0 million of the term loan principal using cash on hand58122 Total Borrowings, Net ($000s) | Category | September 30, 2023 | December 31, 2022 | | :--------------------------------- | :----------------- | :---------------- | | Term loan | $73,406 | $85,000 | | Unamortized debt discounts and issuance costs | $(678) | $(1,455) | | Total debt, net | $72,728 | $83,545 | | Less: Current portion | $(2,125) | $(2,125) | | Long-term debt, net | $70,603 | $81,420 | - As of September 30, 2023, the interest rate on outstanding loans was 7.83%, and the Company had $5.0 million available on its revolving credit facility5960 NOTE 5 – LEASES This note provides information on the company's operating lease commitments, primarily for real estate - The Company's operating leases are primarily for real estate, including medical office suites and corporate offices, with initial terms typically ranging from five to ten years6263 Rent Expense ($000s) | Category | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--------------------------------- | :------------------------------ | :------------------------------ | :----------------------------- | :----------------------------- | | Medical office suites | $1,500 | $1,300 | $4,400 | $3,400 | | Corporate offices | $91 | $91 | $273 | $254 | Future Minimum Rental Payments ($000s) | Year ended December 31, | Amount | | :------------------------ | :----- | | 2023 (remaining) | $1,387 | | 2024 | $6,226 | | 2025 | $6,395 | | 2026 | $6,025 | | 2027 | $5,422 | | Thereafter | $12,190| | Total lease payments | $37,645| | Less: imputed interest | $(9,479)| | Total lease obligations | $28,166| NOTE 6 – STOCKHOLDERS' EQUITY AND EQUITY-BASED COMPENSATION This note details changes in stockholders' equity and the company's equity-based compensation plans - The Company granted 767,261 Restricted Stock Units (RSUs) and 674,846 Performance-Based Stock Units (PSUs) during the nine months ended September 30, 20236667 - RSUs have time-based vesting (1/3 per year over three years), while PSUs have market-based vesting tied to relative Total Shareholder Return (rTSR)6667 Equity-Based Compensation Expense ($000s) | Period | 2023 | 2022 | | :--------------------------------- | :----- | :----- | | Three Months Ended September 30 | $4,492 | $7,370 | | Nine Months Ended September 30 | $13,483| $22,000| Dividends and Distributions Paid ($000s) | Category | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--------------------------------- | :----------------------------- | :----------------------------- | | Dividends paid to shareholders | $200 | $22,800 | | Distributions to EBS Parent, LLC | $100 | $1,200 | NOTE 7 – EARNINGS PER SHARE This note provides a breakdown of basic and diluted earnings per share calculations Basic and Diluted EPS and Weighted Average Shares Outstanding | Metric | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--------------------------------- | :------------------------------ | :------------------------------ | :----------------------------- | :----------------------------- | | Net income/(loss) ($000s) | $(1,667) | $(7,377) | $95 | $(7,487) | | Weighted average shares outstanding - basic | 56,785,087 | 55,640,154 | 56,661,903 | 55,640,154 | | Weighted average shares outstanding - diluted | 56,785,087 | 55,640,154 | 58,329,685 | 55,640,154 | | Income/(loss) per share - basic and diluted | $(0.03) | $(0.13) | $0.00 | $(0.13) | - Potentially dilutive shares, including 661,723 RSUs and 1,697,842 PSUs for the three months ended September 30, 2023, were excluded from diluted EPS calculation as their inclusion would have been antidilutive73 NOTE 8 – INCOME TAXES This note details the company's income tax expense and effective tax rates Income Tax Expense ($000s) and Effective Tax Rate | Metric | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--------------------------------- | :------------------------------ | :------------------------------ | :----------------------------- | :----------------------------- | | Income tax expense | $800 | $4,200 | $2,500 | $4,100 | | Effective tax rate | (89.2)% | (134.6)% | 96.4% | (119.9)% | - The primary reason for the difference between the effective and statutory tax rates is non-deductible executive compensation under Section 162(m) of the Internal Revenue Code74 - There were no uncertain tax positions as of September 30, 2023, or December 31, 202274 NOTE 9 – COMMITMENTS AND CONTINGENCIES This note discusses the company's legal actions, medical malpractice claims, and potential financial impacts - The Company is involved in legal actions and proceedings, primarily medical malpractice claims, which are considered ordinary course of business75 - Management believes the outcome of these actions will not have a material adverse effect on its financial condition, results of operations, or cash flows75 - While the Company maintains liability insurance, there is no assurance that coverage will be adequate for future claims, and liabilities exceeding coverage could materially impact the business76 NOTE 10 – SEGMENT INFORMATION This note clarifies that the company operates as a single reportable segment focused on direct medical procedure services - The Company operates as a single reportable segment: direct medical procedure services, which includes facilities and medical staff providing patented AirSculpt® procedures77 - The Chief Operating Decision Maker (CODM) reviews consolidated financial information, including revenue, gross profit, and Adjusted EBITDA, for performance assessment and resource allocation78 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This section provides an overview of AirSculpt Technologies, Inc.'s financial condition and results of operations, highlighting key operational metrics, non-GAAP financial measures, and a detailed comparison of financial performance Overview This section provides a high-level summary of the company's business and key financial highlights - AirSculpt is a fast-growing national provider of body contouring procedures using its proprietary AirSculpt® method82 - The company expanded its footprint by opening five new centers between March and September 2023, bringing the total to 27 centers across 18 states, Canada, and the UK as of November 13, 202382 Key Financial Highlights ($000s) | Metric | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--------------------------------- | :------------------------------ | :------------------------------ | :----------------------------- | :----------------------------- | | Revenue | $46,793 | $38,892 | $148,309 | $128,090 | | Revenue Growth | 20.3% | N/A | 15.8% | N/A | | Cases Performed | 3,426 | 2,879 | 11,252 | 9,726 | Key Operational and Business Metrics This section presents key performance indicators related to the company's operations and business growth Total Case and Revenue Metrics | Metric | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--------------------------------- | :------------------------------ | :------------------------------ | :----------------------------- | :----------------------------- | | Cases | 3,426 | 2,879 | 11,252 | 9,726 | | Case growth | 19.0% | N/A | 15.7% | N/A | | Revenue per case | $13,658 | $13,509 | $13,181 | $13,170 | | Revenue per case growth | 1.1% | N/A | 0.1% | N/A | | Number of facilities | 27 | 20 | 27 | 20 | | Number of total procedure rooms | 57 | 43 | 57 | 43 | Same-Center Case and Revenue Metrics | Metric | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--------------------------------- | :------------------------------ | :------------------------------ | :----------------------------- | :----------------------------- | | Cases | 2,994 | 2,879 | 9,434 | 9,462 | | Case growth | 4.0% | N/A | (0.3)% | N/A | | Revenue per case | $13,679 | $13,507 | $13,194 | $13,142 | | Revenue per case growth | 1.3% | N/A | 0.4% | N/A | | Number of facilities | 20 | 20 | 18 | 18 | | Number of total procedure rooms | 43 | 43 | 38 | 38 | Non-GAAP Financial Measures—Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Net Income per Share This section defines and reconciles non-GAAP financial measures used by management to assess performance - Adjusted EBITDA is defined as net income/(loss) excluding depreciation and amortization, net interest expense, income tax expense/(benefit), restructuring and related severance costs, IPO related costs, (gain)/loss on disposal of long-lived assets, and equity-based compensation90 - Adjusted Net Income is defined as net income/(loss) excluding restructuring and related severance costs, IPO related costs, (gain)/loss on disposal of long-lived assets, equity-based compensation, and the tax effect of these adjustments91 Adjusted EBITDA and Margin Reconciliation ($000s) | Metric | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--------------------------------- | :------------------------------ | :------------------------------ | :----------------------------- | :----------------------------- | | Net (loss)/income | $(1,667) | $(7,377) | $95 | $(7,487) | | Adjustments (e.g., Equity-based comp, D&A, Interest, Tax) | $10,742 | $15,462 | $33,048 | $38,491 | | Adjusted EBITDA | $9,075 | $8,085 | $33,143 | $31,004 | | Adjusted EBITDA Margin | 19.4% | 20.8% | 22.3% | 24.2% | Adjusted Net Income and Per Share Reconciliation ($000s) | Metric | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--------------------------------- | :------------------------------ | :------------------------------ | :----------------------------- | :----------------------------- | | Net (loss)/income | $(1,667) | $(7,377) | $95 | $(7,487) | | Adjustments (e.g., Equity-based comp, Restructuring, Tax effect) | $4,744 | $6,696 | $15,506 | $21,975 | | Adjusted net income | $3,073 | $(681) | $15,601 | $14,488 | | Adjusted net income/(loss) per share - Basic | $0.05 | $(0.01) | $0.28 | $0.26 | | Adjusted net income/(loss) per share - Diluted | $0.05 | $(0.01) | $0.27 | $0.26 | Results of Operations This section analyzes the company's financial performance by comparing key income statement items across periods Three Months Ended September 30, 2023 Compared to Three Months Ended September 30, 2022 This subsection compares the company's financial results for the three months ended September 30, 2023, against the same period in 2022 - Revenue increased by $7.9 million (20.3%) to $46.8 million, driven by the addition of seven de novo centers and 5.3% same-center revenue growth97 - Cost of service increased by $3.3 million (22.1%) to $18.2 million, primarily due to new center openings, remaining consistent at 38.8% of revenue98 - Selling, general and administrative expenses rose by $1.6 million (7.0%) to $25.0 million, attributed to increased marketing and corporate support for expansion, partially offset by lower equity-based compensation99 - As a percentage of revenue, SG&A decreased from 60.2% to 53.5%99 - Depreciation and amortization increased to $2.6 million from $2.0 million due to the seven additional de novo centers102 - Net loss improved significantly to $(1.7) million from $(7.4) million in the prior year period17 Nine Months Ended September 30, 2023 Compared to Nine Months Ended September 30, 2022 This subsection compares the company's financial results for the nine months ended September 30, 2023, against the same period in 2022 - Revenue increased by $20.2 million (15.8%) to $148.3 million, primarily due to the addition of seven de novo centers106 - Cost of service increased by $9.1 million (19.3%) to $56.1 million, mainly due to the new de novo centers107 - As a percentage of revenue, cost of service rose from 36.7% to 37.9%, reflecting higher initial costs for new centers107 - Selling, general and administrative expenses increased by $3.2 million (4.4%) to $76.8 million, driven by marketing and corporate support for expansion, offset by lower equity-based compensation108 - As a percentage of revenue, SG&A decreased from 57.4% to 51.8%108 - Depreciation and amortization increased to $7.5 million from $5.8 million due to the seven additional de novo centers111 - Interest expense increased to $5.5 million from $4.8 million due to rising interest rates112 - The Company reported a net income of $95 thousand, a significant improvement from a net loss of $(7.5) million in the prior year period17 Liquidity and Capital Resources This section discusses the company's ability to generate and manage cash, including its sources and uses of funds - The Company relies on cash flows from operations and a $5.0 million revolving credit facility for liquidity114 - Primary cash needs include payroll, marketing, rent, and capital expenditures for new centers and procedure rooms114 - As of September 30, 2023, cash and cash equivalents were $8.7 million, with $5.0 million available under the revolving credit facility115 Cash Flow Summary This table provides a summary of cash flows from operating, investing, and financing activities Cash Flows Provided By (Used For) ($000s) | Activity | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--------------------------------- | :----------------------------- | :----------------------------- | | Operating activities | $19,090 | $17,807 | | Investing activities | $(8,092) | $(10,726) | | Financing activities | $(11,954) | $(24,828) | | Net decrease in cash and cash equivalents | $(956) | $(17,747) | Operating Activities This subsection details the cash generated or used by the company's core business operations - Operating cash flow increased by $1.3 million for the nine months ended September 30, 2023, compared to the same period in 2022, driven by the addition of seven de novo centers117 - Working capital improved to $(3.4) million at September 30, 2023, from $(5.6) million at December 31, 2022117 Investing Activities This subsection describes the cash flows related to the acquisition and disposal of long-term assets - Net cash used in investing activities decreased to $8.1 million for the nine months ended September 30, 2023, from $10.7 million in the prior year, primarily due to expansion of existing facilities and opening of de novo locations118 Financing Activities This subsection outlines the cash flows related to debt, equity, and dividend transactions - Net cash used in financing activities decreased to $12.0 million for the nine months ended September 30, 2023, from $24.8 million in the prior year119120 - This decrease was mainly due to a voluntary prepayment of $10.0 million on the term loan in 2023, compared to $22.8 million in dividends and $1.2 million in distributions paid in 2022119120 Long-Term Debt This subsection provides details on the company's long-term debt obligations and related activities - Total indebtedness, net of unamortized deferred financing costs, was $72.7 million as of September 30, 2023, down from $83.5 million at December 31, 2022121 - The Company voluntarily prepaid $10.0 million of the term loan principal on September 29, 2023122 - The term loan bears interest based on a base rate or SOFR plus an applicable margin, with the interest rate at 7.83% as of September 30, 2023123 JOBS Act Accounting Election This section explains the company's election regarding accounting standards under the JOBS Act - As an 'emerging growth company' under the JOBS Act, AirSculpt Technologies, Inc. has irrevocably elected not to use the extended transition period for complying with new or revised financial accounting standards, thus adhering to the same standards as other public companies124 Critical Accounting Policies and Estimates This section confirms that there have been no material changes to the company's critical accounting policies and estimates - There have been no material changes in the nature or application of the Company's critical accounting policies and estimates from those disclosed in its Annual Report on Form 10-K dated March 10, 2023126 Item 3. Quantitative and Qualitative Disclosures About Market Risk As a smaller reporting company, AirSculpt Technologies, Inc. is not required to provide quantitative and qualitative disclosures about market risk - The Company is a smaller reporting company and is not required to provide quantitative and qualitative disclosures about market risk127 Item 4. Controls and Procedures This section details management's evaluation of the Company's disclosure controls and procedures, confirming their effectiveness and noting no material changes in internal controls over financial reporting Management's Evaluation of Disclosure Controls and Procedures This subsection confirms management's assessment of the effectiveness of the company's disclosure controls and procedures - Management, under the supervision of the principal executive and financial officers, concluded that the Company's disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2023129 Changes in Internal Controls Over Financial Reporting This subsection reports on any material changes to the company's internal controls over financial reporting - There were no changes in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, its internal control over financial reporting during the quarter ended September 30, 2023130 Limitations on the Effectiveness of Controls This subsection acknowledges the inherent limitations of any control system, providing only reasonable assurance of achieving control objectives - Management acknowledges that any control system has inherent limitations, providing only reasonable, not absolute, assurance of achieving control objectives131133 - Factors such as faulty judgment, simple error, circumvention by individuals, collusion, or management override can affect control effectiveness131133 PART II OTHER INFORMATION Item 1. Legal Proceedings This section addresses the Company's involvement in legal actions and proceedings, primarily medical malpractice claims, which are considered routine - The Company is involved in pending and threatened legal actions, mostly medical malpractice claims, which are considered ordinary and routine135 - Management believes these will not have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows135 - Claims are generally covered by insurance beyond deductibles, but there is no assurance that coverage will be adequate for all future liabilities135 Item 1A. Risk Factors This section states that there have been no material changes to the risk factors previously discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 - There were no material changes to the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022136 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds This section indicates that there were no unregistered sales of equity securities or use of proceeds to report for the period - None137 Item 3. Defaults Upon Senior Securities This section reports that there were no defaults upon senior securities during the period - None138 Item 4. Mine Safety Disclosures This section states that mine safety disclosures are not applicable to the Company - Not applicable139 Item 5. Other Information This section indicates that there is no other information to report for the period - None140 Item 6. Exhibits This section lists the exhibits filed with the Quarterly Report on Form 10-Q, including certifications from the Principal Executive Officer and Principal Financial Officer, and various Inline XBRL documents - The report includes certifications from the Principal Executive Officer and Principal Financial Officer (Exhibits 31.1, 31.2, 32.1, 32.2) and various Inline XBRL documents (Exhibits 101.INS, 101.SCH, 101.CAL, 101.DEF, 101.LAB, 101.PRE, 104)143145 Signatures This section confirms the official signing of the report by the company's Chief Financial Officer - The report was signed on November 13, 2023, by Dennis Dean, Chief Financial Officer (Principal Accounting and Financial Officer) of AirSculpt Technologies, Inc.147148
AirSculpt Technologies(AIRS) - 2023 Q3 - Quarterly Report